NR3C1 and cancer: Since it activates GR TR without inducing GR TA, it exhibits anti-cancer and anti-inflammatory effects on different in vitro and in vivo models [11,17,27], while, in contrast to GCs, it has fewer side effects related to the function of the hypothalamic–pituitary–adrenal (HPA) axis and bone metabolism [11,27].